Case
Published · Updated · 2 min read
Paclitaxel-based chemoradiotherapy for oropharyngeal Kaposi sarcoma: severe mucositis
What it means for practice
For oropharyngeal Kaposi sarcoma, balance tumour control against mucosal toxicity when considering chemoradiotherapy. In this case, severe oral mucositis required a 15-day hospital admission.
Summary
A 71-year-old HIV-negative man with no known immunodeficiency had Kaposi sarcoma of the left palatine tonsil and cervical lymphadenopathy. He initially presented with odynophagia; a polypoid tonsillar lesion was subsequently identified. Diagnostic tonsillectomy confirmed the diagnosis through histology and immunohistochemistry, with positivity for WT1, CD31, CD34 and human herpesvirus 8 (HHV-8).
Treatment and adverse event
Following discussion by the sarcoma multidisciplinary team, he received radiotherapy at 30 Gy in 15 fractions (2 Gy/fraction), concurrently with weekly paclitaxel as a radiosensitiser. Severe oral mucositis developed after treatment completion. Inability to tolerate oral intake and inadequate pain control required a 15-day hospital admission. Subsequent follow-up magnetic resonance imaging showed a complete response, with no evidence of disease at the time of reporting.
Practical lesson and limitations
The authors emphasise balancing oncological control against the toxicity of combined treatment to the oropharyngeal mucosa. The individual contributions of paclitaxel and radiation to mucositis were not established. They also note that treatment of oropharyngeal Kaposi sarcoma is not standardised because such cases are rare; a stated limitation was the absence of macroscopic photographs of the lesion before surgery. Kaposi sarcoma should be included in the differential diagnosis of atypical tonsillar masses even in the absence of HIV infection or immunosuppression.
Case analysis
- Likely mechanism
- The authors relate severe mucositis to the high sensitivity and fragility of the oropharyngeal mucosa during combined chemoradiotherapy. They do not describe a detailed injury mechanism or distinguish the individual contributions of paclitaxel and radiation.
- Causality assessment
- Editorial WHO-UMC assessment for paclitaxel: possible. Mucositis occurred after treatment completion, but concurrent radiotherapy provides an alternative explanation. Exact onset, the course after treatment withdrawal and rechallenge outcomes are not reported; the authors provide no formal causality assessment.
- Take-home lesson
- A complete tumour response to chemoradiotherapy can be accompanied by severe mucosal toxicity. In this case, mucositis with impaired oral intake and inadequate pain control required prolonged hospitalisation; the reaction cannot be attributed to paclitaxel alone.
Source
-
González Ferraz A, Tolosa Puente A, Gonzalvo Gargallo B, et al. Sarcoma de Kaposi orofaríngeo: a propósito de un caso. Revista Electrónica de PortalesMedicos.com. 2026;XXI(20). doi:10.64396/v21-0220
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
